pegylated liposomal doxorubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   115 Trials   115 Trials   1644 News 


«12...345678910111213...3031»
  • ||||||||||  disulfiram / Generic mfg.
    Trial initiation date:  Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (clinicaltrials.gov) -  Oct 12, 2022   
    P1,  N=24, Not yet recruiting, 
    Collectively, these results provide potential preclinical development process of an alternative approach, new formulation of carrier-free prodrug nanoparticles, for clinical translation of nanomedicines. Initiation date: Sep 2022 --> Dec 2022
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_964;    
    Unlike epithelial ovarian cancer (EOC) BRCA mutations have not been reported in aGCT. In our patient, multiple platinum-sensitive recurrences similar to EOC and subsequent finding of BRCA2 mutation makes a case for further investigation of such aberrations in aGCT with possible therapeutic implications.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    New P1 trial, Metastases:  Doxil/Caelyx BE Study (clinicaltrials.gov) -  Oct 5, 2022   
    P1,  N=36, Not yet recruiting, 
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Trial completion date, Trial primary completion date:  Brentuximab for Newly Diagnosed Hodgkin Disease (clinicaltrials.gov) -  Sep 28, 2022   
    P2,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed | N=213 --> 139 | Trial completion date: Jan 2023 --> Dec 2021 | Trial primary completion date: Jan 2023 --> Dec 2021 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion, Trial completion date:  Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (clinicaltrials.gov) -  Sep 13, 2022   
    P2,  N=26, Completed, 
    This photoimmunochemotherapy is a practical strategy for the treatment of chemoresistant SCLC and should be further investigated for clinical translation. Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Mar 2022
  • ||||||||||  Case Report of a patient with relapsed ovarian cancer and therapy with all three approved PARP-inhibitors (ePoster kiosks (Exhibition area)) -  Sep 12, 2022 - Abstract #ESGO2022ESGO_1323;    
    Even after intolerance of two PARP-inhibitors, another was tolerated, showing that switching PARP-inhibitors during therapy is possible. Patients react differently to side effects of PARP-inhibitors, further studies should focus on predictive clinical and pharmacodynamic parameters to identify individual toxicity for optimization of the efficacy of PARP-inhibitors.Keywords: recurrent HGSOC, multiple PARP inhibitors, BRCA1 mutation, maintenance therapy, case report
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    A RARE CASE OF INTRA- AND EXTRAHEPATIC CHOLESTASIS IN A PATIENT WITH KAPOSI SARCOMA (Convention Center Exhibit Hall: Rapid Area 2B) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_4184;    
    With continued improvement of HIV treatment, incidence of HIV-associated KS has reduced significantly. However, in patients without treatment or interrupted therapy like our patient, especially those with AIDS, high level of suspicion should be maintained for timely diagnosis and treatment and avoiding future complications.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    PEGYLATED LIPOSOMAL DOXORUBICIN DOES NOT AFFECT CARDIAC FUNCTION IN PATIENTS TREATED FOR GYNECOLOGIC MALIGNANCIES () -  Sep 9, 2022 - Abstract #IGCS2022IGCS_873;    
    Hypertension, BMI, and prior/concurrent bevacizumab treatment did not influence the likelihood of pre-treatment evaluation. Risk of cardiac toxicity from administration of PLD for patients undergoing treatment for gynecologic cancers appears to be low and routine screening does not appear to be warranted, even in the presence of cardiac risk factors.
  • ||||||||||  Preclinical, Journal:  Preparation and in vitro evaluation of thermosensitive liposomes targeting for ovarian cancer. (Pubmed Central) -  Aug 24, 2022   
    The study regimen demonstrated good cardiac tolerance and is an alternative strategy for cardioprotection in patients with HER2-positive eBC. The active targeting liposome showed potential in improving the specificity of thermosensitive liposomes and would be applied in the chemotherapy combined with a thermotherapy.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Journal:  The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity. (Pubmed Central) -  Aug 21, 2022   
    In contrast, larger nanoparticles (200 and 400 nm formulations) had more accumulation in the liver and spleen. This study revealed that 90 nm Caelyx biodistribution profile led to the stronger anti-tumour activity of the drug and hence significant survival extension, and showed the importance of vesicle size in the targeting of nanoparticles to the tumour microenvironment for the treatment of cancer.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    PULMONARY KAPOSI SARCOMA WITH ASSOCIATED RECURRENT CHYLOTHORAX (Convention Center Exhibit Hall: Poster Area) -  Aug 16, 2022 - Abstract #CHEST2022CHEST_1846;    
    Here we present a case of pulmonary KS with accompanying chylothorax. This is not a typical presentation or path to diagnosis for pulmonary KS.
  • ||||||||||  AZD7648 / AstraZeneca
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. (clinicaltrials.gov) -  Aug 11, 2022   
    P1/2,  N=30, Active, not recruiting, 
    Schematic diagram of the whole-body m-PBPK models developed for Doxil in rat and human physiology. Recruiting --> Active, not recruiting | N=192 --> 30 | Trial completion date: Feb 2024 --> Dec 2022 | Trial primary completion date: Feb 2024 --> Dec 2022
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
    Review, Journal, Monotherapy:  Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. (Pubmed Central) -  Jul 30, 2022   
    Three-weekly paclitaxel, given at a dose of 175 mg/m compared to a higher dose,probably reduces the risk of neurotoxicity.We are moderately confident in this result; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. A change to 175 mg/m paclitaxel (from a higher dose), if a three-weekly regimen is used, probably has little or no negative impact on PFS or OS (very low-certainty evidence).